CASTLE BIOSCIENCES INC. - COMMON STOCK

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

28 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

25 Apr 2025 16:15:00 By Nasdaq GlobeNewswire

Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

14 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

08 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

07 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

03 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

01 Apr 2025 16:30:00 By Nasdaq GlobeNewswire

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

28 Mar 2025 16:15:00 By Nasdaq GlobeNewswire